Differential effects of the adenosine A1 receptor allosteric enhancer PD 81,723 on agonist binding to brain and adipocyte membranes

Brain Research

Volumn 840, Issue 1-2, 1999, Pages 75-83

  Jarvis, Michael F ^a   Gessner, George ^a   Shapiro, Gary ^a   Merkel, Linda ^a   Myers, Michael ^a   Cox, Bryan F ^a   Martin, Gregory E ^a  

^a SANOFI   (France)

Author keywords

A1 receptor; Adenosine; Adipocyte; Allosterism; PD 81,723

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; CYCLOHEXYLADENOSINE; TRITIUM;

ADIPOCYTE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN MEMBRANE; CONTROLLED STUDY; DOG; GUINEA PIG; MEMBRANE BINDING; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ADENOSINE; ADIPOCYTES; ALLOSTERIC REGULATION; ANIMALS; BRAIN; DOGS; GUINEA PIGS; KINETICS; MALE; MEMBRANES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC P1; THIOPHENES;

EID: 0033523421     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01747-3     Document Type: Article

References (32)

1. 1 adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J. Pharmacol. Exp. Ther. 266:1993;611-617.
2. Appleman J.R., Erion M.D. The therapeutic potential of agents acting via purine receptors. Expert Opin. Invest. Drugs. 7:1998;225-243.
3. 1 adenosine receptors. Mol. Pharmacol. 50:1996;104-111.
4. Bhattacharya S., Linden J. The allosteric enhancer, PD 81,723, stabilizes human A1 adenosine receptor coupling to G proteins. Biochim. Biophys. Acta. 1265:1995;15-21.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;243-245.
6. Bruns R.F., Fergus J.H. Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:1990;939-949.
7. Bruns R.F., Fergus J.H., Coughenour L.L., Courtland G.G., Pugsley T.A., Dodd J.H., Tinney F.J. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. Mol. Pharmacol. 38:1990;950-958.
8. Bruns R.F. Conformational inductions versus conformational selection: evidence from allosteric enhancers. Trends Pharmacol. Sci. 17:1996;189.
9. Fredholm B.B. Effect of adenosine, adenosine analogs and drugs inhibiting adenosine inactivation on lipolysis in rat fat cells. Acta Physiol. Scand. 102:1978;191-198.
10. J.D. Geiger, F. Parkinson, E.A. Kowaluk, Regulators of endogenous adenosine levels as therapeutic agents, in: K.A. Jacobson, M.F. Jarvis (Eds.), Purinergic Approaches in Experimental Therapeutics, Wiley-Liss, New York, 1997, pp. 55-84.
11. A.P. Ijzerman, N.M. van der Wenden, Modulators of adenosine uptake, release, and inactivation, in: K.A. Jacobson, M.F. Jarvis (Eds.), Purinergic Approaches in Experimental Therapeutics, Wiley-Liss, New York, 1997, pp. 126-148.
12. Janusz C.A., Bruns R.F., Berman R.F. Functional activity of the adenosine binding enhancer, PD 81,723, in the in vitro hippocampal slice. Brain Res. 567:1991;181-187.
13. Janusz C.A., Berman R.F. The adenosine binding enhancer, PD, 81,723, inhibits epileptiform bursting in the hippocampal slice. Brain Res. 619:1993;131-136.
14. M.F. Jarvis, Characterization of P1 (Adenosine) purinoceptors, in: S.J. Enna, M. Williams (Eds.), Current Protocols in Pharmacology, 1998, pp. 1.9.1-1.9.15.
15. Kollis-Baker C., Xu J., Pelleg A., Belardinelli L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ. Res. 75:1994;972-980.
16. Kollis-Baker C., Ruble J., Dennis D., Bruns R.F., Linden J., Belardinelli L. Allosteric enhancer PD 81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ. Res. 75:1994;961-971.
17. Kowaluk E.A., Bhagwat S.S., Jarvis M.F. Adenosine kinase inhibitors. Curr. Pharm. Des. 4:1998;403-416.
18. Lee J.T., Newman W.H., Webb J.G. Adenosine receptors in an enriched fraction of plasma membranes from canine ventricular myocardium. J. Cardiovasc. Pharmacol. 8:1986;621-628.
19. Leung E., Walsh L.K.M., Flippin L.A., Kim E.J., Lazar D.A., Seran C.S., Wong E.H.F., Elgen R.M. Enhancement of adenosine A1 receptor functions by benzoylthiophenes in guinea pig tissues in vitro. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;206-212.
20. J. Linden, Allosteric enhancement of adenosine receptors, in: K.A. Jacobson, M.F. Jarvis (Eds.), Purinergic Approaches in Experimental Therapeutics, Wiley-Liss, New York, 1997, pp. 85-97.
21. Londos C., Cooper D.M.F., Wolff J. Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. U.S.A. 77:1980;2551-2554.
22. Merkel L., Rojas C.J., Jarvis M.F., Cox B.F., Fink C., Smits G.J., Spada A.P., Perrone M.H., Clark K.L. Pharmacological characterization of AMP 579, a novel adenosine A1/A2 receptor agonist and cardioprotective. Drug Dev. Res. 45:1998;30-43.
23. 1 receptor. Am. J. Physiol. 264:1993;H1017-H1022. Heart, Circ. Physiol.
24. 1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723. J. Pharmacol. Exp. Ther. 288:1999;446-454.
25. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492.
26. Ramkumar V., Bumgamer J.R., Jacobson K.A., Stiles G.L. Multiple components of the A1 adenosine receptor-adenylate cyclase system are regulated in rat cerebral cortex by chronic caffeine ingestion. J. Clin. Invest. 82:1988;242-247.
27. Ren H., Stiles G.L. Characterization of the human A1 adenosine receptor gene: evidence for alternative splicing. J. Biol. Chem. 269:1994;3104-3110.
28. Rodbell M. Metabolism of isolated fat cells. J. Biol. Chem. 239:1964;368-375.
29. Tucker A.L., Robeva A.S., Taylor H.E., Holeton D., Bockner M.M., Lynch K.R., Linden J. A1 Adenosine receptors: two amino are responsible for species differences in ligand recognition. J. Biol. Chem. 269:1994;27900-27906.
30. Williams M. Adenosine: the prototypic neuromodulator. Neurochem. Inter. 14:1989;249-264.
31. M. Williams, G. Burnstock, Purinergic neurotransmission and neuromodulation: A historical perspective, in: K.A. Jacobson, M.F. Jarvis (Eds.), Purinergic Approaches in Experimental Therapeutics, Wiley-Liss, New York, 1997, pp. 2-26.
32. Zhang Y., Wells J.N. The effects of chronic caffeine administration on peripheral adenosine receptors. J. Pharmacol. Exp. Ther. 254:1990;757-763.